{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:51:59Z","timestamp":1792093919598,"version":"4.4.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Drug resistance is a major challenge in cancer therapy, especially in hematologic malignancies in which kinase inhibitors have transformed treatment yet are frequently undermined by drug resistance. Although targeted protein degradation (TPD) offers a mechanistically distinct mode of action compared with inhibition-based therapeutic therapies, the potential value of TPD in drug-resistant blood cancer remains unclear. Here, we report the discovery of cereblon (CRBN)\u2013recruiting molecular glue degraders (MGDs) targeting lymphocyte-specific tyrosine kinase (LCK), an oncogenic kinase in T-cell acute lymphoblastic leukemia (T-ALL). By high-throughput screening and medicinal chemistry optimization, we developed a series of MGDs that induced CRBN-dependent degradation of LCK as well as potent cytotoxicity in T-ALL in vitro. Structure-activity relationship analysis and ternary complex modeling revealed a noncanonical degron at the LCK-CRBN interface involving the G-loop, whose mutation disrupts this interaction. Unlike inhibitors and inhibitor-based proteolysis-targeting chimeras, these MGDs engage LCK in regions distal to the ATP-binding site, and thus their activities in T-ALL are not affected by gatekeeper LCK mutations that drive resistance to inhibitor-based therapeutics. Taken together, our data highlight the potential of LCK-targeting MGDs as a strategy to overcome kinase inhibitor resistance in T-ALL, offering a framework for targeting kinase dependencies in drug-refractory hematologic malignancies more broadly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031127","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:02:09Z","timestamp":1781787729000},"page":"739-750","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["LCK-targeting molecular glues overcome resistance to inhibitor-based therapy in T-cell acute lymphoblastic leukemia"],"prefix":"10.1182","volume":"148","author":[{"given":"Satoshi","family":"Yoshimura","sequence":"first","affiliation":[{"name":"1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Actis","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3976-3473","authenticated-orcid":false,"given":"Justin T.","family":"Seffernick","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"McGrath","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie A.","family":"Jarusiewicz","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5165-4571","authenticated-orcid":false,"given":"Yong","family":"Li","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3668-0485","authenticated-orcid":false,"given":"DongGeun","family":"Lee","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Mayasundari","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6866-4290","authenticated-orcid":false,"given":"Zoran","family":"Rankovic","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7179-2581","authenticated-orcid":false,"given":"Marcus","family":"Fischer","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2253-9325","authenticated-orcid":false,"given":"Gisele","family":"Nishiguchi","sequence":"additional","affiliation":[{"name":"2Department of Chemical Biology and Therapeutics, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun J.","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children\u2019s Research Hospital, Memphis, TN"},{"name":"3Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2026080611222431600_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2026080611222431600_bib2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-019-0362-y","article-title":"Development of targeted protein degradation therapeutics","volume":"15","author":"Chamberlain","year":"2019","journal-title":"Nat Chem Biol"},{"issue":"9","key":"2026080611222431600_bib3","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5682","key":"2026080611222431600_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"issue":"8","key":"2026080611222431600_bib5","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci"},{"issue":"20","key":"2026080611222431600_bib6","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1021\/acs.jmedchem.9b01264","article-title":"Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 ubiquitin ligase","volume":"62","author":"Zhao","year":"2019","journal-title":"J Med Chem"},{"key":"2026080611222431600_bib7","doi-asserted-by":"crossref","first-page":"113645","DOI":"10.1016\/j.ejmech.2021.113645","article-title":"Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation","volume":"223","author":"Liu","year":"2021","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2026080611222431600_bib8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"issue":"21","key":"2026080611222431600_bib9","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.3390\/cancers13215506","article-title":"Inhibitors, PROTACs and molecular glues as diverse therapeutic modalities to target cyclin-dependent kinase","volume":"13","author":"Rana","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2026080611222431600_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s43018-020-00167-4","article-title":"Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia","volume":"2","author":"Gocho","year":"2021","journal-title":"Nat Cancer"},{"issue":"24","key":"2026080611222431600_bib11","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood.2024027982","article-title":"Surface pT\u03b1 expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL","volume":"145","author":"Courtois","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026080611222431600_bib12","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1182\/blood-2016-09-738070","article-title":"Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia","volume":"129","author":"Frismantas","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2026080611222431600_bib13","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1038\/bcj.2017.87","article-title":"In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL","volume":"7","author":"Laukkanen","year":"2017","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026080611222431600_bib14","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41375-023-01900-5","article-title":"Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia","volume":"37","author":"Yoshimura","year":"2023","journal-title":"Leukemia"},{"issue":"8","key":"2026080611222431600_bib15","doi-asserted-by":"crossref","first-page":"e29724","DOI":"10.1002\/pbc.29724","article-title":"Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia","volume":"69","author":"He","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"659","key":"2026080611222431600_bib16","doi-asserted-by":"crossref","first-page":"eabo5228","DOI":"10.1126\/scitranslmed.abo5228","article-title":"Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia","volume":"14","author":"Hu","year":"2022","journal-title":"Sci Transl Med"},{"issue":"14","key":"2026080611222431600_bib17","doi-asserted-by":"crossref","first-page":"11868","DOI":"10.1021\/acs.jmedchem.4c00481","article-title":"Development of an orally bioavailable LCK PROTAC degrader as a potential therapeutic approach to T-cell acute lymphoblastic leukemia","volume":"67","author":"Jarusiewicz","year":"2024","journal-title":"J Med Chem"},{"issue":"4","key":"2026080611222431600_bib18","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/leu.2010.11","article-title":"Lck is a key target of imatinib and dasatinib in T-cell activation","volume":"24","author":"Lee","year":"2010","journal-title":"Leukemia"},{"issue":"2","key":"2026080611222431600_bib19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/acsmedchemlett.2c00436","article-title":"Phenyl dihydrouracil: an alternative cereblon binder for PROTAC design","volume":"14","author":"Jarusiewicz","year":"2023","journal-title":"ACS Med Chem Lett"},{"issue":"3","key":"2026080611222431600_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/crispr.2018.0014","article-title":"EditR: a method to quantify base editing from sanger sequencing","volume":"1","author":"Kluesner","year":"2018","journal-title":"CRISPR J"},{"key":"2026080611222431600_bib21","unstructured":"St. Jude Children\u2019s Research Hospital PROPEL Data Portal. Accessed 5 February 2026. https:\/\/propel.stjude.cloud."},{"issue":"8027","key":"2026080611222431600_bib22","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41586-024-07807-0","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"Polonen","year":"2024","journal-title":"Nature"},{"issue":"1","key":"2026080611222431600_bib23","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41467-024-44698-1","article-title":"Selective CK1\u03b1 degraders exert antiproliferative activity against a broad range of human cancer cell lines","volume":"15","author":"Nishiguchi","year":"2024","journal-title":"Nat Commun"},{"issue":"15","key":"2026080611222431600_bib24","doi-asserted-by":"crossref","first-page":"e4731","DOI":"10.21769\/BioProtoc.4731","article-title":"Ex vivo drug sensitivity imaging-based platform for primary acute lymphoblastic leukemia cells","volume":"13","author":"Rowland","year":"2023","journal-title":"Bio Protoc"},{"issue":"2","key":"2026080611222431600_bib25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acschembio.7b00549","article-title":"CRISPR-mediated tagging of endogenous proteins with a luminescent peptide","volume":"13","author":"Schwinn","year":"2018","journal-title":"ACS Chem Biol"},{"issue":"6755","key":"2026080611222431600_bib26","doi-asserted-by":"crossref","first-page":"eadt6736","DOI":"10.1126\/science.adt6736","article-title":"Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition","volume":"389","author":"Petzold","year":"2025","journal-title":"Science"},{"issue":"13","key":"2026080611222431600_bib27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026080611222431600_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"2026080611222431600_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1146\/annurev-pharmtox-022123-104147","article-title":"From thalidomide to rational molecular glue design for targeted protein degradation","volume":"64","author":"Oleinikovas","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"2026080611222431600_bib30","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/bloodadvances.2020003855","article-title":"Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial","volume":"5","author":"Lowenberg","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026080611222431600_bib31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2011-02-337303","article-title":"A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605","volume":"118","author":"Sekeres","year":"2011","journal-title":"Blood"},{"issue":"9","key":"2026080611222431600_bib32","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"key":"2026080611222431600_bib33","unstructured":"DepMap Public 24Q4 Public. Figshare+. Dataset: DepMap, Broad Institute. 2024. https:\/\/depmap.org\/portal."},{"issue":"1","key":"2026080611222431600_bib34","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1038\/s41467-024-46922-4","article-title":"Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL","volume":"15","author":"Nayak","year":"2024","journal-title":"Nat Commun"},{"issue":"4","key":"2026080611222431600_bib35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.ccell.2023.02.010","article-title":"Dual IKZF2 and CK1\u03b1 degrader targets acute myeloid leukemia cells","volume":"41","author":"Park","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"2026080611222431600_bib36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"issue":"11","key":"2026080611222431600_bib37","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1021\/jacsau.4c00762","article-title":"Development of oral, potent, and selective CK1\u03b1 degraders for AML therapy","volume":"4","author":"Huang","year":"2024","journal-title":"JACS Au"},{"issue":"suppl 1","key":"2026080611222431600_bib38","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2024-209924","article-title":"BMS-986397, a first-in-class molecular glue degrader of casein kinase 1\u03b1 (CK1\u03b1) for the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) harboring functional TP53 [abstract]","volume":"144","author":"Jimenez","year":"2024","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/739\/2536578\/blood_bld-2025-031127-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/739\/2536578\/blood_bld-2025-031127-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:22:46Z","timestamp":1786029766000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/6\/739\/567170\/LCK-targeting-molecular-glues-overcome-resistance"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031127","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,6]]},"published":{"date-parts":[[2026,8,6]]}}}